Hugh Salter

Company: Anocca AB

Job title: Chief Scientific Officer

Seminars:

Modeling Target/Receptor Axis for T Cell Therapy: Scalable Personalised TCR-T 4:15 pm

Development of engineered cancer cells for precise and systematic models to qualitatively map HLA-peptide targets Development of engineered T-cells for systematic determination of HLA-peptide target specific TCR activity Standardization of cell-based analysis platforms facilitating personalised treatment strategiesRead more

day: Conference Day One